Physician profile
Jason E Peters
NPI 1083638779
$4,050.34
in general payments reported to CMS, 2019-2025
32 companies · $532 in 2025
The $532 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $598 · 2020: $860 · 2021: $542 · 2022: $396 · 2023: $337 · 2024: $786 · 2025: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,655.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $968.60 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $771.61 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.65 | 2019-2024 | Jardiance, Ofev |
| Sanofi-Aventis U.S. LLC | $211.97 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $198.43 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $183.53 | 2019-2021 | |
| Pfizer INC. | $170.27 | 2020-2024 | |
| Amgen INC. | $163.46 | 2019-2025 | Otezla, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $162.47 | 2019-2025 | Farxiga |
| Dexcom, INC. | $102.58 | 2021-2025 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $82.45 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $72.21 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $65.55 | 2019-2021 | |
| Mylan Specialty L.P. | $65.02 | 2019-2020 | |
| Allergan, INC. | $62.83 | 2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $60.93 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $58.86 | 2019-2022 | |
| Eisai INC. | $55.70 | 2021 | |
| Glaxosmithkline, LLC. | $47.95 | 2021-2022 | |
| Strongbridge US INC. | $37.42 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $35.39 | 2024 | Rexulti |
| Si-Bone, INC. | $31.73 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $30.34 | 2021-2024 | Keveyis |
| Paratek Pharmaceuticals, INC. | $30.33 | 2022 | |
| Mannkind Corporation | $20.92 | 2020 | |
| Radius Health, INC. | $18.33 | 2020 | |
| Genentech USA, INC. | $17.88 | 2020 | |
| Merck Sharp & Dohme LLC | $17.07 | 2019 | |
| Astellas Pharma US INC | $16.51 | 2024 | Veozah |
| Acadia Pharmaceuticals INC | $15.00 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.30 | 2024 | Xifaxan |
| Abbott Laboratories | $14.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Peters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.